Arkansas Administrative Code
Agency 070 - Board of Pharmacy
Rule 070.00.93-001 - Amendment 9 - Section D, Charitable Clinic Permit; Reg. 32; 36 Non-Equivalent Drug Product List; Reg. 48; 54. Pharmacists Assistants

Universal Citation: AR Admin Rules 070.00.93-001

Current through Register Vol. 49, No. 9, September, 2024

AMENDMENT

9. Section D. Charitable Clinic Permit

By specific Board of Pharmacy action, the Board may authorize charitable clinic permit pharmacies to dispense certain prescription "legend" drugs.

These drugs are limited to birth control medications, drugs to treat tuberculosis, and Metronidazole, Doxycycline Erythromycin to be used only in the sexually transmitted disease treatment program.

Packaged and labeled prescription drugs shall be initialed by the pharmacist to assure accuracy and appropriateness. A licensed nurse may issue these pre-dispensed prescription drugs, by placing the patients name, date of issue and prescription number on the label at the time of issue to patients on order of the physician. The prescription number as placed on the label of the dispensed prescription drug is to be placed with the physician's order in the patients medical record. The pharmacist shall monitor patients medical records to assure that medication profiles and prescription orders are maintained and utilized.

Since the pharmacist is not present when the patient receives the medication, the pharmacists shall develop protocol to assure that the patient is monitored and counseled by the physician or nurse consistent with the requirements of Board of Pharmacy Regulation #48.

AMENDMENT

Regulation 32

8. Pharmacists who wish to retain their license but do not want-to yearly meet continuing education requirements may go on inactive pharmacist status for an indefinite period. To reestablish active status and return to practice, this pharmacst must acquire half of the continuing education missed up to 60 hours.

36. NON-EQUIVALENT DRUG PRODUCT LIST

If a product is listed on the Arkansas Non-Equivalent Drug Product List and the FDA approves a competitive product as bioequivalent and publishes the products with an "A" rating in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book) Arkansas pharmacists may substitute that product consistent with law until this list is revised. Conversely, if the change is from an "A" rating to a "B" rating, the pharmacist may not substitute without the consent of the prescribing physician if the pharmacist is aware of the "B" rating.

A prescription written for any brand name drug listed can only be changed with consent of the prescribing physician. If written generically, once the pharmacist has selected a manufacturers product the physician shall be notified if another company's product is used.

Leucovorin Calcium Tablets

Levothyroxine Tablets

Phenytoin Sodium Tablets and Capsules

Quinidine Gluconate Oral

Theophylline Capsules Controlled Release and Tablets

Warfarin Sodium Tablets

Add significant interations to our list in Board Regulation 48

* Floxin with Theophylline

* Terfenadine with Erythromycin

* Terfenadine with Ketoconazole and Etraconazole

* Astemizole with Erythromycin

* Astemizole with Itraconazole, Ketoconazole

* Gemfibrozil with Simvastatin or Pravastatin

54. Pharmacists Assistants

1. A pharmacist assistant shall register with the Board of Pharmacy on a form approved by the Board and shall renew such registration on January 1, each year.

2. The registration fee shall be $15.00 per annum.

3. The Board will issue a permit for the pharmacist assistant applicable to a specified pharmacy location; said permit cannot be transferred to any other pharmacy location. The permit shall be prominently displayed for public perusal in said pharmacy.

4. Prior to a person beginning work as a pharmacist assistant, whether original employment or a change in employers or locations, he shall submit a registration form to the Board and receive a permit for the specific pharmacy location. The Board may grant a temporary authorization for a pharmacist assistant by telephone or facsimile communication when an immediate need exists which precludes the submission of a registration form in conventional form.

5. A pharmacist assistant shall identify himself as such in any telephone conversation regarding the functions of a pharmacist assistant while on duty in the pharmacy.

6. When a pharmacist assistant leaves the employment of a pharmacy, the pharmacist-in-charge shall notify the Board, in writing, within ten days thereof.

7. If the pharmacist assistant is suspected to have or evidence exists that a pharmacy assistant may have violated any law or regulation regarding the practice of pharmacy, legend drugs or controlled substances, the pharmacist-in-charge shall notify the Board, in writing, within ten days or immediately if any danger to the public health or safety may exist. Any other pharmacist, whether or not practicing in the same pharmacy, who has such knowledge or suspicion, shall notify the Board in a like manner.

8.
(a) The Board may, after notice and hearing, suspend or revoke the permit or a pharmacist assistant upon a finding of the following:
(1) Violation of this regulation.

(2) Violation of any law or regulation regarding the practice of pharmacy

(3) Violation of any law or regulation related to legend drugs or controlled substances.

(4) Failure to conduct himself professionally in conformity with all applicable federal, state, and municipal laws and regulations in his relationship with the public, health care professions, and pharmacists.

(5) Failure to hold to the strictest confidences all knowledge concerning patrons, their prescriptions, and other confidence entrusted or acquired by him; divulging In the interest of the patron, only by proper release forms, or where required for proper compliance with legal authority.

(6) Providing invalid or insufficient checks in payment for licenses or renewals.

(b) The Board shall follow the same procedures for hearings for pharmacist assistants as applicable to hearings for pharmacists as set forth in A.C.A. § 17-91-101 et seq. and Board Regulations.

Disclaimer: These regulations may not be the most recent version. Arkansas may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.